FDG-PET As an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis
Status: Recruiting
Conditions: Myocarditis
Location:
Mayo Clinic in RochesterCity/State:
Rochester, Minnesota
Contact Information:
Clinical Trials Referral Office
Phone Number:
855-776-0015
Email: [email protected]
Brief Summary: The purpose of this pilot study is to evaluate Fluorodeoxyglucose – Positron Emission Tomography (FDG-PET) as an imaging modality to diagnose and risk stratify subclinical, imaging negative ICI-myocarditis, and to determine whether subclinical ICI-induced myocarditis is a distinct and clinically relevant entity with a risk of progression to fulminant myocarditis.